SRF Limited has informed the Exchange regarding 'Strategic Agreements between SRF Limited and The Chemours Company'.
SRF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Midcap 150 and 0.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SRF Limited has signed strategic agreements with The Chemours Company (NYSE: CC), a global chemistry major with USD 5.78 billion in CY2024 turnover, to collaborate on manufacturing and marketing advanced fluoropolymers and fluoroelastomers. SRF will produce these materials at its Dahej facility, with production expected to begin in roughly 12 months. The multi-year arrangement targets global markets including semiconductors, automotive, aerospace, chemical processing, and oil and gas. Chemours will use SRF's manufacturing capacity to expand its global supply flexibility without upfront capital investment, while SRF strengthens its position in advanced fluorochemicals.
This is a positive development for SRF shareholders as it validates its fluoropolymer manufacturing capabilities, brings a marquee global partner on board, and opens a new high-value revenue stream from the Dahej facility serving premium end-markets like semiconductors and aerospace. The deal should support earnings visibility over the multi-year contract period and could trigger a re-rating of SRF's fluorochemicals segment.